A Web-Based Collaborative Drug Discovery Platform
Barry Bunin, Ph.D.
CEO and President
Collaborative Drug Discovery, Burlingame, CA.
www.collaborativedrug.com
bbunin@collaborativedrug.com
© 2009 Collaborative Drug Discovery, Inc.
Archive,
Mine, Drug
Collaborate
Copyright © 2011 All Rights Reserved
Collaborative
Discovery
© 2009 Collaborative Drug Discovery, Inc.
Archive, Mine, Collaborate
© 2009 Collaborative Drug Discovery, Inc.
Archive, Mine, Collaborate
Knowledge-Based Drug Discovery
Public and proprietary data sources
Chemistry
Actual
Libraries
Virtual
Libraries
SAR
QSAR Models
Knowledge
Base
Other Models
Email results
Selection / Optimization
© 2009 Collaborative Drug Discovery, Inc.
Archive, Mine, Collaborate
© 2009 Collaborative Drug Discovery, Inc.
Archive, Mine, Collaborate
CDD History
© 2009 Collaborative Drug Discovery, Inc.
Archive, Mine, Collaborate
CDD for Private, Collaborative, & Public Research
• Users: 21,197 unique logins last year (scalable in the cloud)
• Interoperability/Standards: csv/SMILES, sdfiles, PubMed,
ChemSpider-Pubchem, REST Based Architecture for APIs
• Employing technology to facilitate partnerships: both pre- and
post-IP agreements supported
• Expanding the precompetitive space: the key is supporting
traditional (IP sensitive), collaborative (pre-IP), and open (post-IP) –
all these are real use cases
© 2009 Collaborative Drug Discovery, Inc.
Archive,
Mine, Drug
Collaborate
Copyright © 2011 All Rights Reserved
Collaborative
Discovery
© 2009 Collaborative Drug Discovery, Inc.
Archive, Mine, Collaborate
CDD Vault for Your Own Private Data
© 2009 Collaborative Drug Discovery, Inc.
Archive,
Mine, Drug
Collaborate
Copyright © 2009 All Rights Reserved
Collaborative
Discovery
Data Partitioning for Multiple Collaborations
Collaborator 1
ec
Pr
oj
Company A
A
j e ct
Pro
tB
Consolidated
CDD DB
Collaborator 2
© 2009 Collaborative Drug Discovery, Inc.
Pr
oj
ec
tC
Proj
e ct D
Collaborator 3
Collaborator 4
Archive,
Mine, Drug
Collaborate
Copyright © 2009 All Rights Reserved
Collaborative
Discovery
Collaborative Capabilities for
Efficient International Drug Discovery
Individual Pain Points
Organizational Need
Technical Solution
Keep scientist’s data
private until ready to
share (i.e. with the rest of
their groups)
Collaboration is as much
about more efficient work
within a single
organization as between
organizations.
Temporal data access
controls
Allow scientists to
partition or sequester data
to enable selective data
sharing
Control of chemical or
biological data access
based on Project-specific
permissions
Spatial data partitioning
Allow collaboration in
scientist’s natural
workflow (i.e. without
uploading data multiple
times in multiple places)
Control based on type of
data – especially given a
marketplace with
specialization in
synthesis, screening,
discovery, development
Sequester by data
classification
© 2009 Collaborative Drug Discovery, Inc.
Archive,
Mine, Drug
Collaborate
Copyright © 2011 All Rights Reserved
Collaborative
Discovery
Back Pocket
© 2009 Collaborative Drug Discovery, Inc.
Archive, Mine, Collaborate
© 2009 Collaborative Drug Discovery, Inc.
User Roles and Privileges in CDD
© 2009 Collaborative Drug Discovery, Inc.
Archive, Mine, Collaborate
CDD Convenient Mining & Export Options
© 2009 Collaborative Drug Discovery, Inc.
Archive, Mine, Collaborate
CDD Configurable IC50 Dose Response Capabilities
© 2009 Collaborative Drug Discovery, Inc.
Archive, Mine, Collaborate
Data Mining
© 2009 Collaborative Drug Discovery, Inc.
Archive, Mine, Collaborate
Secure and Low TCO (Total Cost of Ownership)
CDD database system
• Web based (log in securely into to your database from any
computer).
• We host the server for you
• Highly secure, all traffic encrypted, server in a secure
professionally hosted environment.
© 2009 Collaborative Drug Discovery, Inc.
Archive,
Mine, Drug
Collaborate
Copyright © 2009 All Rights Reserved
Collaborative
Discovery
CDD Drug Repurposing 2009 Case Study #1
Result
New leads reveal known
drugs that reverse
chloroquine resistance
© 2009 Collaborative Drug Discovery, Inc.
Archive, Mine, Collaborate
CDD BMGF TB PPP: Case Study #2
 3 Academia/ Govt lab – Industry screening partnerships
 CDD used for data sharing / collaboration
© 2009 Collaborative Drug Discovery, Inc.
Archive, Mine, Collaborate
CDD 2011 EU PPP Case Study #3
© 2009 Collaborative Drug Discovery, Inc.
Archive, Mine, Collaborate
Why CDD?
•
Network
– Traction: thousands of leading researchers log into CDD today:
– Academic customers: Harvard, Columbia, Johns Hopkins, UCSF (new assays)
– Pharmas relationships: Pfizer, GSK, Novartis, Lilly (commercial partners)
– Startups
– Research institutes, Non profits NIH, BMGF, MM4TB etc
•
Neutral
– Trusted for >7 years in the cloud
– Moral high-ground due to years dedicated to neglected disease (TB w/ Gates Foundation)
– Credible position
•
IP
– CDD handles data corresponding to composition of matter & utility patents
– Templates for rapid web-based transactions (IP corresponding to data)
– CDD does not own IP
© 2009 Collaborative Drug Discovery, Inc.
Archive, Mine, Collaborate
Collaboration is everywhere
Major collaborative grants in EU: Framework, IMI …NIH moving in same direction
Cross continent collaboration CROs in China, India etc –
Pharma’s in US / Europe
More industry – academia collaboration ‘not invented here’ a thing of the past
More effort to go after rare and neglected diseases -Globalization and connectivity of
scientists will be key –
Current pace of change in pharma may not be enough.
Need to rethink how we use all technologies & resources…
© 2009 Collaborative Drug Discovery, Inc.
Archive, Mine, Collaborate
Models and software becoming more accessible- free, precompetitive efforts collaboration
© 2009 Collaborative Drug Discovery, Inc.
Archive, Mine, Collaborate
Drug Toxicity Alerts
© 2009 Collaborative Drug Discovery, Inc.
Archive, Mine, Collaborate
What if you could…
1. Spend only 20% on descriptors and algorithms
2. Selectively share your models with collaborators and control access
3. Have someone else host the models / predictions
Current investments
>$1M/yr
>$10-100’s M/yr
Inside company
Collaborators
© 2009 Collaborative Drug Discovery, Inc.
Archive,
Mine, Drug
Collaborate
Copyright © 2009 All Rights Reserved
Collaborative
Discovery
Yes we can…predictions now
can be shared without revealing structures!
© 2009 Collaborative Drug Discovery, Inc.
Archive, Mine, Collaborate
CDD SBIR to Selectively Share Predictive
Models Across Industry and Academia
© 2009 Collaborative Drug Discovery, Inc.
Archive, Mine, Collaborate
The benefit to Big Pharma
The ability to profile any external drug candidates where others have invested
substantial resource, with little to no work from Big Pharma using ADME/Tox models,
to pick and choose and prioritize the most interesting projects for in licensing.
P.S. NIH could fund the automation, streamlining, and scaling the approach once
proven successful (and Big Pharma would benefit without having the cost of
development).
© 2009 Collaborative Drug Discovery, Inc.
Archive, Mine, Collaborate
CDD support of international collaborations
•
•
•
•
Capabilities to selectively collaborate from an “IP-neutral” party
Selective sharing and data partitioning are needed.
Web2.0 informatics collaborative “processes” matter.
The infrastructure capabilities determine what is possible and
practical.
• CDD capabilities support diverse PDP and PPPs.
– Proven in more effective collaborations
© 2009 Collaborative Drug Discovery, Inc.
Archive,
Mine, Drug
Collaborate
Copyright © 2011 All Rights Reserved
Collaborative
Discovery
Summary
• What is implemented in software guides common business
rules and creates efficiencies.
• CDD has lowered the barriers to archive and collaborate –
instead of frustration after deciding what “makes sense”,
collaboration occurs naturally and instantaneously.
• Collaborative informatics provides cohesiveness when scaling
collaborative efforts.
• Unique collaborative technologies allow groups with diverse
IP/data requirements to work together, as if one.
© 2009 Collaborative Drug Discovery, Inc.
Archive,
Mine, Drug
Collaborate
Copyright © 2011 All Rights Reserved
Collaborative
Discovery
Take Home
“CDD makes the distinction between pre-competitive,
competitive, and non-competitive drug discovery...irrelevant.”
Barry Bunin, Ph.D.
CEO and President
Collaborative Drug Discovery, Burlingame, CA.
www.collaborativedrug.com
bbunin@collaborativedrug.com
© 2009 Collaborative Drug Discovery, Inc.
Archive,
Mine, Drug
Collaborate
Copyright © 2011 All Rights Reserved
Collaborative
Discovery